Patents by Inventor Vladimir Kral
Vladimir Kral has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11331281Abstract: Mixture of stabilised biologically available curcumin for orodispersible formulations, formulations of biologically available curcumin and orodispersible tablet with biologically available curcumin and its application. An orodispersible tablet with biologically available curcumin contains particles of extract of rhizome of plant Curcuma longa, which contains, at least, 95% by weight of curcumin, grounded to size 100 to 250 nm in mixture with mannitol in weight ratio 1 to 3:1 (mannitol:curcumin). Orodispersible tablet also contains an orodispersible carrier, and curcumin 100% biologically available through oral mucosa.Type: GrantFiled: May 7, 2018Date of Patent: May 17, 2022Inventors: Jan Stonis, Ivan Mikes, Andrea Dolezalova, Jarmila Kralova, Milan Jakubek, Pavel Martasek, Vladimir Kral
-
Publication number: 20180325842Abstract: Orodispersible tablet with biologically available curcumin containing particles of extract of rhizome of plant Curciuma longa containing, at least, 95% by weight of curcumin ground to size 100 to 250 nm in mixture with mannitol in ratio 1 to 3:1 (mannitol:curcumin) on orodispersible carrier, and curcumin of the extract 100% biologically available through oral mucosa.Type: ApplicationFiled: May 7, 2018Publication date: November 15, 2018Applicants: mcePharma s. r. o., IMCoPharma a. s.Inventors: Jan Stonis, Ivan Mikes, Andrea Dolezalova, Jarmila Kralova, Milan Jakubek, Pavel Martasek, Vladimir Kral
-
Patent number: 10031835Abstract: Code block rating for guilty changelist identification and test script suggestion is discussed herein. An embodiment operates by assigning, by at least one processor, a respective code block rating to each code block of a plurality of code blocks; determining, by at least one processor, a change list rating for a change list, wherein the determining comprises: assigning, by at least one processor, a respective suspicious code block rating to each code block of the plurality of the code blocks modified by the change list, wherein the respective suspicious code block rating of a code block is based upon the respective code block rating of the code block, and calculating, by at least one processor, the change list rating based upon the respective code block ratings of each code block modified by the change list; and performing, by at least one processor, maintenance on the change list based upon the calculated change list rating.Type: GrantFiled: September 28, 2016Date of Patent: July 24, 2018Assignee: SAP SEInventor: Vladimir Kral
-
Publication number: 20180089063Abstract: Code block rating for guilty changelist identification and test script suggestion is discussed herein. An embodiment operates by assigning, by at least one processor, a respective code block rating to each code block of a plurality of code blocks; determining, by at least one processor, a change list rating for a change list, wherein the determining comprises: assigning, by at least one processor, a respective suspicious code block rating to each code block of the plurality of the code blocks modified by the change list, wherein the respective suspicious code block rating of a code block is based upon the respective code block rating of the code block, and calculating, by at least one processor, the change list rating based upon the respective code block ratings of each code block modified by the change list; and performing, by at least one processor, maintenance on the change list based upon the calculated change list rating.Type: ApplicationFiled: September 28, 2016Publication date: March 29, 2018Inventor: Vladimir KRAL
-
Patent number: 8013190Abstract: The present invention provides novel HIV protease inhibitors containing substituted borane, carborane or metallacarborane clusters with 6 to 12 boron atoms in each cluster. The charge of each borane, carborane or metallacarborane cluster is 0, ?1 or ?2. The number of borane, carborane or metallacarborane clusters in the inhibitor molecule is 1 to 9, and the carborane clusters in metallacarborane inhibitors are coordinated to transition metal atom, selected from the group containing cobalt, iron, nickel and ruthenium. In the cluster, heteroatoms can be present, such as nitrogen, phosphorus, silicon, germanium, tin and sulphur. The present invention covers pharmaceutical compositions containing these inhibitors and their use, both in vitro and in vivo. They are characterized by high effectiveness and stability.Type: GrantFiled: January 27, 2005Date of Patent: September 6, 2011Assignees: Vysoka Skola Chemicko-Technologicka V Praze, Ustav Organicke Chemie A Biochemie AV CZ, Ustav Anorganicke Chemie AV CZ, Department of Virology, University of HeidelbergInventors: Vladimír Král, Petr Cigler, Jan Konvalinka, Milan Kozísek, Jana Prejdová, Bohumír Grüner, Jaromír Plesek, Martin Lepsík, Jana Pokorná, Hans-Georg Kräusslich, Jochen Bodem
-
Publication number: 20100291689Abstract: A group of water-soluble salophene-lanthanide complexes and other salophene-metal complexes are useful for purposes including: (i) detecting neutral carbohydrates at physiologically-relevant pH, (ii) the selective detection of gangliosides, and (iii) the selective detection of lysophosphatidic acid (LPA) in the presence of phosphatidic acid. The selective detection of LPA is useful in diagnosing ovarian and other cancers.Type: ApplicationFiled: March 14, 2007Publication date: November 18, 2010Applicants: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY & AGRICULTURAL AND MECHANICAL COLLEGE, INSTITUTE OF CHEMICAL TECHNOLOGYInventors: Robert M. Strongin, Onur Alptürk, Oleksandr Rusin, Sayo O. Fakayode, Jorge O. Escobedo Cordova, Weihua Wang, Isiah M. Warner, William E. Crowe, Vladimir Král
-
Publication number: 20090012044Abstract: The present invention provides novel HIV protease inhibitors containing substituted borane, carborane or metallacarborane clusters with 6 to 12 boron atoms in each cluster. The charge of each borane, carborane or metallacarborane cluster is 0, ?1 or ?2. The number of borane, carborane or metallacarborane clusters in the inhibitor molecule is 1 to 9, and the carborane clusters in metallacarborane inhibitors are coordinated to transition metal atom, selected from the group containing cobalt, iron, nickel and ruthenium. In the cluster, heteroatoms can be present, such as nitrogen, phosphorus, silicon, germanium, tin and sulphur. The present invention covers pharmaceutical compositions containing these inhibitors and their use, both in vitro and in vivo. They are characterized by high effectiveness and stability.Type: ApplicationFiled: January 27, 2005Publication date: January 8, 2009Applicants: VYSOKA SKOLA CHEMICKO-TECHNOLOGICKA V PRAZE, USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CZ, USTAV ANORGANICKE CHEMIE AV CZ, DEPARTMENT OF VIROLOGY, UNIVERSITY OF HEIDELBERGInventors: Vladimir Kral, Petr Cigler, Jan Konvalinka, Milan Kozisek, Jana Prejdova, Bohumir Gruner, Jaromir Plesek, Martin Lepsik, Jana Pokorna, Hans-Georg Krausslich, Jochen Bodem
-
Patent number: 7122572Abstract: The present invention provides calixpyrrole, calixpyridinopyrrole, and calixpyridine macrocycles, having 4, 5, 6, 7, or 8 heterocyclic rings, as well as syntheses, derivatives, conjugates, multimers, and solid supports thereof. Such macrocycles have proved to be effective and selective ion- and neutral molecule-binding agents forming supramolecular ensembles, and ion- and neutral molecule-separation agents. The macrocycles are fully meso-non-hydrogen-substituted porphyrinogens, a few molecules of which were previously known but not recognized as possessing anion- or molecule-binding properties. The binding mode is noncovalent, primarily that of hydrogen-bonding, thereby providing a new mode for liquid chromatography, that of Hydrogen Bonding Liquid Chromatography. Further useful applications of the macrocycles provided herein include environmental remediation by removal of undesired ions or neutral molecules, and removal of phosphate for kidney dialysis.Type: GrantFiled: April 20, 2001Date of Patent: October 17, 2006Assignee: Board of Regents, University of Texas SystemInventors: Philip A. Gale, Jonathan L. Sessler, Vladimír A. Král, Andrei Andrievsky, Vincent Lynch, Petra I. Sansom, William E. Allen, Christopher T. Brown, Andreas Gebauer
-
Publication number: 20020026047Abstract: The present invention provides calixpyrrole, calixpyridinopyrrole, and calixpyridine macrocycles, having 4, 5, 6, 7, or 8 heterocyclic rings, as well as syntheses, derivatives. conjugates, multimers, and solid supports thereof. Such macrocycles have proved to be effective and selective ion- and neutral molecule-binding agents forming supramolecular ensembles, and ion- and neutral molecule-separation agents. The macrocycles are fully meso-non-hydrogen-substituted porphyrinogens, a few molecules of which were previously known but not recognized as possessing anion- or molecule-binding properties. The binding mode is noncovalent, primarily that of hydrogen-bonding, thereby providing a new mode for liquid chromatography, that of Hydrogen Bonding Liquid Chromatography. Further useful applications of the macrocycles provided herein include environmental remediation by removal of undesired ions or neutral molecules, and removal of phosphate for kidney dialysis.Type: ApplicationFiled: April 20, 2001Publication date: February 28, 2002Inventors: Philip A. Gale, Jonathan L. Sessler, John W. Genge, Vladimir A. Kral, Andrei Andrievsky, Vincent Lynch, Petra I. Sansom, William E. Allen, Christopher T. Brown, Andreas Gebauer
-
Patent number: 6262257Abstract: The present invention provides calixpyrrole, calixpyridinopyrrole, and calixpyridine macrocycles, having 4, 5, 6, 7, or 8 heterocyclic rings, as well as syntheses, derivatives, conjugates, multimers, and solid supports thereof. Such macrocycles have proved to be effective and selective ion- and neutral molecule-binding agents forming supramolecular ensembles, and ion- and neutral molecule-separation agents. The macrocycles are fully meso-non-hydrogen-substituted porphyrinogens, a few molecules of which were previously known but not recognized as possessing anion- or molecule-binding properties. The binding mode is noncovalent, primarily that of hydrogen-bonding, thereby providing a new mode for liquid chromatography, that of Hydrogen Bonding Liquid Chromatography. Further useful applications of the macrocycles provided herein include environmental remediation by removal of undesired ions or neutral molecules, and removal of phosphate for kidney dialysis.Type: GrantFiled: April 4, 1997Date of Patent: July 17, 2001Assignee: Board of Regents, University of Texas SystemInventors: Philip A. Gale, Jonathan L. Sessler, John W. Genge, Vladimír A. Král, Andrei Andrievsky, Vincent Lynch, Petra I. Sansom, William E. Allen, Christopher T. Brown, Andreas Gebauer
-
Patent number: 5969111Abstract: Texaphyrins substituted with imidazda are provided.Type: GrantFiled: February 4, 1997Date of Patent: October 19, 1999Assignees: Board of Regents, The University of Texas System, Pharmacyclics, Inc.Inventors: Jonathan L. Sessler, Gregory W. Hemmi, Tarak D. Mody, Darren Magda, Vladimir A. Kral
-
Patent number: 5955586Abstract: The present invention is directed to highly boronated derivatives of expanded porphyrins including sapphyrins and texaphyrins, and more particularly to expanded porphyrins substituted with carborane clusters. Such compositions are useful in boron neutron capture therapy, radiation therapy, photodynamic therapy, and other applications.Type: GrantFiled: March 20, 1997Date of Patent: September 21, 1999Inventors: Jonathan L. Sessler, William E. Allen, Vladimir A. Kral
-
Patent number: 5808059Abstract: The invention relates to the field of polymer- and other matrix-supported sapphyrins. Disclosed are silica gel, glass, resin and other polymer- and matrix-supported sapphyrins and sapphyrin-containing chromatographic and electrophoretic supports.Type: GrantFiled: August 28, 1995Date of Patent: September 15, 1998Assignee: Board of Regents, University of Texas SystemInventors: Jonathan L. Sessler, Brent L. Iverson, Vladimir Kral, Kevin Shreder, Hiroyuki Furuta, Richard E. Thomas
-
Patent number: 5801229Abstract: Texaphyrins are provided for use as radiation sensitizers. Advantageous properties of texaphyrins for use as a radiation sensitizer include: i) a low redox potential which allows radiation-induced hydrated electrons to flow to texaphyrin rather than neutralizing hydroxyl radicals, allowing hydroxyl radicals to cause cellular damage, ii) a relatively stable texaphyrin radical that reacts readily to covalently modify neighboring molecules causing further cellular damage, iii) intrinsic biolocalization, and iv) indifference to the presence or absence of O.sub.2. These properties allow texaphyrins to be particularly effective for treating the hypoxic areas of solid neoplasms. Methods of treatment for an individual having a neoplasm or atheroma include the use of a texaphyrin as a radiation sensitizer and as an agent for photodynamic tumor therapy, or the use of a texaphyrin for internal and for external ionizing radiation. Novel texaphyrins are provided.Type: GrantFiled: September 13, 1996Date of Patent: September 1, 1998Assignee: The Board of Regents, University of Texas SystemInventors: Jonathan L. Sessler, Tarak D. Mody, Gregory W. Hemmi, Vladimir A. Kral
-
Patent number: 5744302Abstract: The present invention provides various novel covalently modified sapphyrin derivatives and conjugates; polymers including sapphyrin or derivatives thereof; and chromatographic supports including sapphyrins and other expanded porphyrins and derivatives thereof. Disclosed are water soluble sapphyrins, including polyhydroxysapphyrins and sapphyrin-sugar derivatives; sapphyrin-metal chelating conjugates; sapphyrin nucleobase conjugates; oligosapphyrins and polysapphyrins, including sapphyrin dimers, trimers, oligomers and higher polymers; and polymer supported expanded porphyrin compositions, including advantageous rubyrin- and sapphyrin-based chromatography columns and electrophoretic supports. Sapphyrin oligomers and polymers and polymer supported expanded porphyrins, such as, e.g.Type: GrantFiled: May 11, 1995Date of Patent: April 28, 1998Assignee: Board of Regents, The University of Texas SystemInventors: Jonathan L. Sessler, Brent L. Iverson, Vladimir Kral, Kevin Shreder, Hiroyuki Furuta, Richard E. Thomas
-
Patent number: 5672490Abstract: The present invention provides various novel covalently modified sapphyrin derivatives and conjugates; polymers including sapphyrin or derivatives thereof; and chromatographic supports including sapphyrins and other expanded porphyrins and derivatives thereof. Disclosed are water soluble sapphyrins, including polyhydroxysapphyrins and sapphyrin-sugar derivatives; sapphyrin-metal chelating conjugates; sapphyrin nucleobase conjugates; oligosapphyrins and polysapphyrins, including sapphyrin dimers, trimers, oligomers and higher polymers; and polymer supported expanded porphyrin compositions, including advantageous rubyrin- and sapphyrin-based chromatography columns and electrophoretic supports. Sapphyrin oligomers and polymers and polymer supported expanded porphyrins, such as, e.g.Type: GrantFiled: June 2, 1995Date of Patent: September 30, 1997Assignee: The University of Texas Board of RegentsInventors: Jonathan L. Sessler, Brent L. Iverson, Vladimir Kral, Kevin Shreder, Hiroyuki Furuta, Richard E. Thomas
-
Patent number: 5583220Abstract: Texaphyrins are provided for use as radiation sensitizers. Advantageous properties of texaphyrins for use as a radiation sensitizer include: i) a low redox potential which allows radiation-induced hydrated electrons to flow to texaphyrin rather than neutralizing hydroxyl radicals, allowing hydroxyl radicals to cause cellular damage, ii) a relatively stable texaphyrin radical that reacts readily to covalently modify neighboring molecules causing further cellular damage, iii) intrinsic biolocalization, and iv) indifference to the presence or absence of O.sub.2. These properties allow texaphyrins to be particularly effective for treating the hypoxic areas of solid neoplasms. Methods of treatment for an individual having a neoplasm or atheroma include the use of a texaphyrin as a radiation sensitizer and as an agent for photodynamic tumor therapy, or the use of a texaphyrin for internal and for external ionizing radiation. Novel texaphyrins are provided.Type: GrantFiled: May 24, 1995Date of Patent: December 10, 1996Assignees: Pharmacyclics, Inc., Board of Trustees, Univ. of TX Sys.Inventors: Jonathan L. Sessler, Anthony M. Harriman, Richard A. Miller, Tarak D. Mody, Gregory W. Hemmi, Vladimir A. Kral, Darren Magda
-
Patent number: 5543514Abstract: Sapphyrins are provided having appended functional groups that render the sapphyrin water-soluble. Such water-soluble sapphyrins are useful for photodynamic therapy, for example.Type: GrantFiled: April 6, 1995Date of Patent: August 6, 1996Assignee: Board of Regents, The University of Texas SystemInventors: Jonathan L. Sessler, Vladimir Kral
-
Patent number: 5530123Abstract: The present invention provides various covalently modified sapphyrin derivatives and conjugates, and also, polymers including sapphyrin or derivatives thereof. Disclosed are water soluble sapphyrins, including polyhydroxysapphyrins and sapphyrin-sugar derivatives; sapphyrin-metal chelating conjugates; sapphyrin nucleobase conjugates; and polymer supported sapphyrins. Novel sapphyrin dimers, trimers, oligomers and polymers are also described, which polymers may include repeating units of sapphyrin or sapphyrin derivatives alone, or may further incorporate other units such as nucleobases.Type: GrantFiled: October 11, 1994Date of Patent: June 25, 1996Assignee: Board of Regents, The University of Texas SystemInventors: Jonathan L. Sessler, Brent L. Iverson, Vladimir Kral, Kevin Shreder, Hiroyuki Furuta
-
Patent number: 5457183Abstract: A method of using texaphyrins as radiosensitizers. Advantageous properties of texaphyrins for use as a radiosensitizer include i) a low redox potential which allows radiation induced solvated electrons to flow to texaphyrin rather than neutralizing hydroxyl radicals, allowing the hydroxyl radicals to cause cellular damage, ii) a relatively stable texaphyrin radical which, nevertheless, reacts readily to covalently modify neighboring molecules causing further cellular damage, and iii) intrinsic biolocalization and indifference to the presence of O.sub.2 which allow texaphyrin to be particularly effective for treating the hypoxic areas of solid tumors. Sensitizer enhancement ratios of 1.62 and 2.2 were achieved at 20 .mu.M and 80 .mu.M gadolinium-texaphyrin, respectively, with a mouse leukemia cell line.Type: GrantFiled: October 12, 1993Date of Patent: October 10, 1995Assignee: Board of Regents, The University of Texas SystemInventors: Jonathan L. Sessler, Tarak D. Mody, Gregory W. Hemmi, Vladimir Kral